Nexiguran ziclumeran

Gene therapy / editing

Also known as NTLA-2001

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Phase 3underway

Evidence outlook · registrational

Transthyretin Amyloidosis with Cardiomyopathy: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2027-12.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (2)
Transthyretin Amyloidosis with Cardiomyopathy
NCT06128629 · Intellia Therapeutics
2023-12-13 – 2028-04 · Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
What this study did
Other / comorbidity
NCT06672237 · Intellia Therapeutics
2024-11-22 – 2028-08 · Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease, Neurodegenerative Disease, Hereditary, Neurodegenerative Diseases, Neuromuscular Diseases, Nerve Disorders, Nervous System Disease, Nervous System Diseases, Genetic Disease, Inborn, Amyloidosis, Familial, Amyloidosis, Hereditary, Amyloidosis, Polyneuropathies, Amyloid Neuropathies, Amyloid Neuropathies, Familial, Peripheral Nervous System Disease, Peripheral Nervous System Diseases, Metabolism, Inborn Errors, Metabolic Diseases
What this study did
Phase 1 (1)
Transthyretin Amyloidosis with Cardiomyopathy
NCT04601051 · Intellia Therapeutics
2020-11-05 – 2025-09-12 · Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis
What this study did

Competitive landscape

This mechanism is crowded: 8 other tracked programmes target it, 5 of them ahead of this one.

This drug's own stage for Transthyretin Amyloidosis with Cardiomyopathy: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Nexiguran Ziclumeran: this drugPhase 3Gene therapy / editingTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
Acoramidis (Attruby)ApprovedSmall moleculeTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
Patisiran (ONPATTRO)
Approved(overall)
RNA / oligonucleotideTransthyretin (TTR)
Reliable signal(overall)
NCT03997383: Change From Baseline at Month 12 in Six-Minute Walk Test (6-MWT) (Baseline, Month 12): Placebo (DB)/Patisiran (OLE) -21.345 meters (95% CI -68.268 to 12.75) | Patisiran (DB+OLE) -8.15 meters (95% CI -54.651 to 29.51)
Vutrisiran (AMVUTTRA)ApprovedRNA / oligonucleotideTransthyretin (TTR)Reliable signal
NCT04153149: Composite of all-cause mortality and recurrent cardiovascular events: overall population HR 0.718 (95% CI 0.555 to 0.929), p=0.0118; vutrisiran monotherapy subgroup HR 0.672 (95% CI 0.487 to 0.929), p=0.0162
Inotersen (Tegsedi)
US approval withdrawn(overall)
RNA / oligonucleotideTransthyretin (TTR)
Reliable signal(overall)
No reviewed efficacy summary in this indication
CliramitugPhase 3Monoclonal antibodyTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication
Coramitug
Phase 3(overall)
Monoclonal antibodyTransthyretin (TTR)
not yet graded(overall)
No reviewed efficacy summary in this indication
Eplontersen (Wainua)Phase 3RNA / oligonucleotideTransthyretin (TTR)Partial signal
NCT04136171: CARDIO-TTRansform primary composite: rate ratio 0.89 (95% CI 0.73 to 1.09), P=0.28; no significant reduction. missed
NucresiranPhase 3RNA / oligonucleotideTransthyretin (TTR)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Nexiguran ziclumeran to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
July 2027 (1)
Phase 3Neuromuscular Disease, Neuromuscular Diseases (NMD), Neurodegenerative Disease, Neurodegenerative Disease, Hereditary …Active not recruiting
Est. primary completion 2027-07 · NCT06672237 · CT.gov ↗
What to watch
December 2027 (1)
Phase 3Transthyretin Amyloidosis with CardiomyopathyRecruiting
Est. primary completion 2027-12 · NCT06128629 · CT.gov ↗
What to watch

See the full readout calendar ↗